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An anti-cancer derivative of butyric acid
(pivalyloxymethyl butyrate) and daunorubicin
cooperatively prolong survival of mice inoculated with
monocytic leukaemia cells
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Summary A derivative of butyric acid, pivalyloxymethyl butyrate (AN-9), inhibited the proliferation and induced apoptosis of mouse
monocytic leukaemia Mm-A cells, although sodium butyrate, but not AN-9, induced differentiation of the cells. AN-9 and DNA-specific
antineoplastic agents synergistically inhibited the growth of Mm-A cells, and the simultaneous treatment was required to evoke the maximum
growth-inhibitory effect. On the other hand, there was no synergy between butyrate and the drugs, or AN-9 and anti-metabolic agents in
inhibiting the growth of the cells, suggesting that the synergistic effect is specific to AN-9 and DNA-reacting agents. AN-9 as a single agent
prolonged the survival of mice inoculated with Mm-A cells in a dose-dependent manner. Moreover, administration of AN-9 plus daunorubicin
(DNR) markedly prolonged their survival. These results suggest that combination with AN-9 and DNR entails an obvious therapeutic potential.
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Butyric acid, a non-toxic natural product found in food and present
in the digestive system as a byproduct of microbial fermentation,
has been shown to be an effective inducer of differentiation in a
variety ofhaematopoietic and non-haematopoietic malignant cells
(Prasad, 1980). Clinical trials were conducted with sodium
butyrate on haematopoietic malignancies (Novogradsky et al,
1983). It induced a partial and temporary remission in a child with
acute myeloid leukaemia (AML), although no clinical activity of
butyrate was detected in nine adults with acute leukaemia (Miller
et al, 1987). The lack of clinical efficacy may be caused by its
rapid metabolism, and to a lesser extent, to its excretion. In order
to overcome these disadvantages, a search for novel prodrugs of
butyrate, which would impart reduction in clearance rates, was
undertaken, and we developed a prodrug, AN-9, which exhibited
much greater anti-cancer activity than butyrate in vitro and in vivo
(Nudelman et al, 1992; Rephaeli et al, 1991).
Some DNA-specific antileukaemic drugs induced differentia-
tion of leukaemia cells in conjunction with non-toxic differentia-
tion inducers (Okabe et al, 1979; Honma et al, 1986). The two
components interact synergistically and differentiation can, there-
fore, be induced at concentrations at which neither drug nor
inducer, administered alone, are capable of effecting differentia-
tion to a significant extent. Since differentiation is accompanied by
the loss ofproliferative capacity, a chemodifferentiation approach,
based on drug-non-toxic inducer interactions, holds therapeutic
promise.
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The remission rate of acute monocytic leukaemia (AMMOL) is
lower than that of the other types ofAML, and even when remis-
sion is achieved by treatment with conventional cytotoxic
antileukaemic drugs, the median duration of remission is only
about 6 months (Fenaux et al, 1990). Therefore, it is important to
develop new strategies for control of AMMOL that are refractory
to conventional cytotoxic antileukaemic drugs. The mouse mono-
cytic leukaemia Mm-A cells are leukaemogenic to syngeneic mice
and can phagocyoise sensitized sheep erythrocytes, produce
lysozyme and adhere to culture dishes (Kasukabe et al, 1984). The
experimental system is provided to study therapeutic strategies for
monocytic leukaemia. Butyrate was the most effective agent for
increasing lysozyme production by Mm-A cells, and it also stimu-
lated other differentiation-associated functions (Kasukabe et al,
1985). In the primary culture ofAML cells, butyrate was effective
in inducing morphological and functional differentiation of
leukaemia cells in some cases obtained from AMMOL patients
(Honma et al, 1983; Rephaeli et al, 1994). These results suggest
that butyrate and/or its derivatives may be useful in the therapy of
AMMOL. In the present investigation, we have compared the
effect ofbutyrate and its derivative, AN-9, on the proliferation of
Mm-A cells in conjunction with some antileukaemic drugs, and
examined the therapeutic effect of AN-9 on mice inoculated with
Mm-A cells.
MATERIALS AND METHODS
Materials
AN-9 was prepared from butyric acid and chloromethyl pivalate
in the presence of triethyl amine (Nudelman et al, 1992) and
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Figure 1 Effects of sodium butyrate and AN-9 on the growth and lysozyme
production of Mm-A cells. Cells were cultured with various concentrations of
sodium n-butyrate (open symbols) or AN-9 (closed symbols) for 4 days
dissolved in dimethyl sulphoxide. Daunorubicin (DNR), doxoru-
bicin, actinomycin D, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-
tetrazolium (MTT) and nitroblue tetrazolium (NBT) were
purchased from Sigma (St Louis, MO, USA).
Cells and cell culture
Mouse monocytic leukaemia Mm-A cells were cultured in Eagle's
minimum essential medium with 10% heat-inactivated calf serum
at 37°C in a humidified atmosphere of 5% carbon dioxide in air
(Kasukabe et al, 1984). Human myeloid leukaemia cell lines were
cultured in RPMI-1640 medium with 10% heat-inactivated fetal
bovine serum (Makishima et al, 1991; Okabe-Kado et al, 1991).
Assay of cell growth, differentiation-associated
properties and apoptosis
Suspensions of cells (5 x 104 cells per ml) were cultured with
various concentrations oftestchemicals in 24-well culture dishes for
4-6 days. Then, cell numbers were counted in a model ZM Coulter
counter (Coulter Electronics, Luton, UK). Viable cells were exam-
ined by MIT assay, as described previously (Kanatani etal, 1993).
Lysozyme activity and NBT reduction were assayed as reported
previously (Kanatani et al, 1993). Morphological changes were
examined in cell smears stained with May-Gruenwald-Giemsa
solution.
Animals
Inbred SL strain mice were maintained as previously reported and
female mice were used at 8-10 weeks old (Honma et al, 1978).
The mice were inoculated i.p. with 6 x 106 Mm-A cells per animal.
Administration of AN-9 and DNR
For the assay of in vivo antileukaemic effect of AN-9, it was
prepared in 20% Intralipid (Green Cross, Osaka, Japan). DNR was
dissolved in phosphate-buffered saline. The mice were given i.p.
20 Table 1 Growth-inhibitory effect of butyrate and AN-9 on several myeloid
leukaemia cells
Cells Growth inhibition (IC5., RM)
Butyrate AN-9
Mouse
Mm-A (monocytoid) 253 ± 18 105 + 11
Human
HL-60 (promyelocytic) 691 ± 54 51 ± 7
U937 (monocytoid) 943 ± 87 148 ± 18
THP-1 (monocytoid) 741 ± 69 140 ± 16
HEUS (monocytoid) 869 ± 78 119 ± 12
Cells were cultured with various concentrations of sodium butyrate or AN-9
for 4 days, and the concentration of the drug required for 50% inhibition of
cell growth (IC50) was examined. Values are mean ± s.d.
injections of0.2 ml ofeach solution at doses of 2.5 mg per mouse
(109 mg kg-') ofAN-9 and 3 ,ug per mouse (130gg kg-') ofDNR.
The first dose was administered 1 day after the leukaemia cell
inoculation.
Analysis of combined drug effects
Isobologram analysis was the basis for analysing combined drug
effects with leukaemia cells (Berenbaum, 1989). Dose effects were
determined for each compound and for one compound in fixed
concentrations of another one. The interaction of two compounds
was quantified by determining a combination index (CI) value
according to the classic isobologram equation. This analysis
generates the combination effect as: summation (additivity or zero
interaction) is indicated when CI = 1; synergism is indicated when
CI < 1; antagonism is indicated when CI > 1.
RESULTS
Combined effect of AN-9 and DNR on proliferation of
Mm-A cells
AN-9 inhibited the growth of Mm-A cells at lower concentrations
than sodium n-butyrate (Figure 1). Butyrate effectively enhanced
lysozyme production of Mm-A cells, as described previously
(Kasukabe et al, 1985), whereas AN-9 did not affect lysozyme
production ofthe cells, even in a high concentration. Nor did AN-
9 induce differentiation as assessedby othermarkers, such as NBT
reduction (data not shown), although AN-9 induced NBT reduc-
tion of human myeloid leukaemia HL-60 cells (Rephaeli et al,
1991). The AN-9-treated Mm-A cells became non-adherent, and
morphological examination revealed shrivelled cells, chromatin
condensation, nuclear fragmentation and cytoplasmic blebbing in
the culture of Mm-A cells treated with AN-9 for 7 days. These
results indicate that AN-9 induced apoptosis rather than differenti-
ation of Mm-A cells. Next, we examined the growth-inhibitory
effect ofAN-9 on various leukaemia cell lines. Table 1 shows that
HL-60 cells were the most sensitive to the growth-inhibitory
activity of AN-9, while Mm-A cells were more sensitive to
butyrate than HL-60 cells. With respect to growth inhibition by
AN-9, Mm-A cells were more sensitive than human monocytoid
leukaemia U937, HEL/S and THP-1 cells. Lysozyme production
of the monocytoid leukaemia cells was induced by butyrate, but
not by AN-9 (data not shown). These results suggestthat the effect
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Table 2 Synergy between AN-9 and various anti-cancer drugs in growth
inhibition of Mm-A cells
ICM(M)
Drug - AN-9 + AN-9 CIa
DNR 1.06 x 10-7 0.44 x 10-7 0.49
Doxorubicin 6.79 x 10-8 3.45 x 10-8 0.53
Actinomycin D 1.27 x 10-9 0.48 x 10-9 0.48
Cytosine arabinoside 2.07 x 10-7 2.32 x 10-7 1.03
Methotrexate 1.10 x 10-7 1.16 x 10-7 1.06
6-Mercaptopurine 6.58 x 10-8 6.56 x 10-8 0.99
5-Fluorouracil 7.69 x 10-7 7.81 x 10-7 1.08
Etoposide 6.38x 10-7 6.42x 10-7 1.04
Cells were cultured with various concentrations of antineoplastic agents in
the presence or absence of 30gM AN-9. aCombination index at IC50. Cl = 1
indicates summation (additive or zero interaction), Cl > 1 antagonism, Cl < 1
synergism.
Table 3 Effect of sequence of application of various combinations of DNR
and AN-9 on the proliferation of Mm-A cells
Regimen Additions on Cell number on day 6
Days 1-3 Days 4-6 x 1O5 ml-' Percentage of control
1 None None 14.2± 1.6 100
2 AN-9 None 14.0± 1.8 99
3 None AN-9 14.3 ± 1.7 100
4 AN-9 AN-9 12.4± 1.3 87
5 DNR None 11.2 ± 1.1 79
6 None DNR 12.5 ± 1.4 87
7 DNR DNR 8.8± 0.9 62
8 DNR AN-9 10.0± 1.2 70
9 AN-9 DNR 12.6 ± 1.5 89
10 AN-9 + DNR None 3.3 ± 0.5 23
11 None AN-9 + DNR 9.4± 1.1 66
Cells were cultured for 3 days in the absence or presence of 20 ng ml-' DNR
or 46.5 gM AN-9. On day 3, the cultures were washed with fresh medium and
reincubated in the presence or absence of the same concentration of DNR
or AN-9.
of AN-9 is different from that of butyrate in monocytoid
leukaemia cells.
When Mm-A cells were cultured with 20 ng ml' DNR for 4
days, the growth was hardly affected. In the presence of low
concentrations of AN-9, DNR-induced growth inhibition was
evident, whereas butyrate did not affect DNR-induced growth
inhibition of Mm-A cells (Figure 2). These synergistic effects
between AN-9 and DNR were also observed in 3-day treatment
(data not shown). Next, we examined the combined effect of
various anti-cancer drugs with AN-9 on the growth ofMm-A cells.
Actinomycin D and doxorubicin were also effective in the syner-
gistic inhibition of growth in the presence of AN-9, whereas no
I I synergistic effect with AN-9 was observed in combination with
5 10 15 20 25 cytosine arabinoside, 5-fluorouracil, methotrexate, etoposide or 6-
DNR (ng ml-1) mercaptopurine (Table 2). Expression ofdifferentiation-associated
phenotypes of Mm-A cells was not significantly affected by the
combined treatment with AN-9 and DNR (data not shown).
ombined effect of sodium butyrate orAN-9 with DNR on the Treatment of the cells with AN-9 for 3 days caused no significant
Im-A cells. Cellswere cultured with various concentrations of decrease in cell numbers (Table 3, regimens 2 and 3). When AN-9
presence of 0 (-), 30 (-), 45 (A) or 60 (*) gM AN-9 for 4 days
rere cultured with DNR in the presence of 0 (E), 0.1 (0), 0.2 (A) was added for an additional 3 days (regimen 4), the cell number
iM sodium butyrate for 4 days (B) decreased very slightly. At the concentration of AN-9 used, cell
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Table 4 Effect of AN-9 on survival times of mice inoculated with Mm-A cells
Experiment Dose No.of
(mg per mouse) mice Survival (days ± s.d.) T/Ca
0 10 22.3±2.8
3 5 36.8±6.5* 165
11 0 20 21.7 ±1.6
1 5 21.6±2.4 100
2.5 10 31.7 ±3.6** 146
III 0 10 22.6±2.2
2.5 5 30.9± 5.9* 137
5 5 40.4±7.1** 179
SL mice were inoculated with 6 x 106 Mm-A cells and treated with AN-9
every other day. aRatio of survival days of treated mice to those of solvent
control. *P< 0.01, **P< 0.001, using Student's t-test. In experiment 1, 50%
propylene glycol was used as solvent instead of 20% Intralipid.
DNR
AN-9
0 10 20 30 40 50
AN-9 + DNR
I.........................;
.............-...................-.......
I I 1
60 70 80
Days
Figure 3 Effects of AN-9 and DNR on the survival of SL mice inoculated with
monocytic leukaemia Mm-A cells. SL female mice were inoculated i.p. with
6 x 106 Mm-A cells. One day after the inoculation, the mice were treated with
solvent alone (-), 2.5 mg of AN-9 (--), 3 9g of DNR (-- - -) or AN-9 plus
DNR (...) every other day. Administration of DNR was done on days 1, 3,
5 and 7, and AN-9 was administered 11 times. Ten mice were used in a
group of 'solvent alone' or 'AN-9 plus DNR', and five mice were used in a
group of 'AN-9' or 'DNR'. The survival time of mice treated with AN-9
plus DNR was prolonged more than that of mice treated with AN-9 alone
(P < 0.05, log-rank test)
viability was in excess of 95% (data not shown). When the cells
were cultured with DNR for 3 days (regimens 5 and 6), the growth
decreased slightly, whereas the administration of a second dose of
DNR on day 3 (regimen 7) caused significant inhibition of cell
growth. Treatment of the cells for 3 days with DNR, followed by a
3-day exposure to AN-9 (regimen 8) resulted in a more
pronounced decrease in cell number than the administration of
AN-9 before DNR (regimen 9). When the drug and AN-9 were
administered simultaneously (regimen 10), approximately 77%
growth inhibition was observed. When the DNR-AN-9 combina-
tion was applied for the second 3 days (regimen 11), the growth
inhibition was similar to that in regimen 7. These results indicate
that the simultaneous treatment is the most effective in combina-
tions of DNR and AN-9.
Effect of AN-9 on the survival of mice inoculated with
Mm-A cells
After inoculation of 6 x 106Mm-A cells, all the mice died of
leukaemia within 30 days. At necropsy, the abdomen of mice
contained a large amount of ascites with numerous Mm-A cells,
and many small tumour nodules were scattered on the liver
surface, mesentery and peritoneum. In some cases, splenomegaly
and hepatic colonization of the leukaemia cells were observed, as
in AMMOL patients (Shaw, 1978). To test the effect of AN-9
alone on the leukaemogenicity of the monocytic leukaemia cells,
we administered AN-9 i.p. to syngeneic SL mice inoculated with
Mm-A cells. Since AN-9 possesses low toxicity (LD50 in mice is
1.36 g kg-') (Rephaeli et al, 1991), no appreciable side-effect was
observed in our experiments. AN-9 significantly prolonged the
mean survival time of mice inoculated with Mm-A cells, and the
therapeutic effect ofAN-9 was dose dependent (Table 4).
Mice inoculated with the monocytic leukaemia cells were
injected with DNR, a representative antileukaemic agent, the first
injection being given 1 day after tumour challenge. This treatment
significantly prolonged the survival of the mice (Figure 3).
Although the drug was fairly toxic to SL mice when injected with
a higher dose of DNR, all the mice treated with 3 jig of DNR
survived for a long time (more than 3 months), and no appreciable
side-effects were observed.
Next, we examined the therapeutic effect ofthe combined treat-
ment with AN-9 and DNR. The median survival time of mice
inoculated with Mm-A cells was 31 days on treatment with AN-9
only, but 47 days on treatment with 2.5 mg of AN-9 and 3 jg of
DNR (P < 0.05, log-rank test)(Figure 3). The in vivo finding on
the prolongation of survival times is compatible with that on the
synergistic effect ofAN-9 and DNR on the growth ofthe cells.
DISCUSSION
AN-9 is a butyric acid prodrug, but its effect on the growth and
differentiation of monocytic leukaemia cells is different from that
of butyrate. Butyrate and AN-9 modulated the expression of the
early regulating genes, c-myc and c-jun, but AN-9 elicited this
effect at least 100 times faster than butyrate (Rabizadeh et al,
1993). This may be caused by a faster rate ofintracellular penetra-
tion by the lipophilic AN-9 and/or a slower rate of metabolic
degradation. The in vitro and in vivo antileukaemic activity of
AN-9 may be attributable to its pharmacokinetic properties.
With respect to the growth-inhibitory effect, there was synergy
between AN-9 (but not butyrate) and DNA-specific antineoplastic
agents, such as DNR, doxorubicin and actinomycin D, but there
was no synergy between AN-9 and other anti-cancer drugs, such
as etoposide, methotrexate, 6-mercaptopurine and cytosine arabi-
noside. These results suggest that the synergistic effect was
specific to DNA-reacting agents in conjunction with AN-9.
Simultaneous treatment with AN-9 and DNR was required to
evoke the maximum effect in inhibiting the growth ofMm-A cells.
Both AN-9 and butyrate caused a transient hyperacetylation of
histones, and AN-9 induced at a concentration one order ofmagni-
tude lower than butyrate (Aviram et al, 1994). The kinetics ofAN-
9-induced histone acetylation were faster than those of butyrate.
The histone hyperacetylation loosened the chromatin structure
(Lee etal, 1993), and this may improve the accessibility ofDNR to
nucleosomal DNA. A reversible increase ofhistone acetylation by
AN-9 and the requirement of simultaneous treatment with AN-9
and DNR are compatible with this view. Alternatively, there may
be a reasonable mechanism in which AN-9 has synergy with inter-
calating agents, such as DNR, doxorubicin and actinomycin D, but
not other classes of antineoplastic agents. However, the mecha-
nism of interaction between DNA-specific antineoplastic agents
and AN-9 remains to be elucidated.
AMMOL is more refractory to conventional cytotoxic anti-
leukaemic drugs than other subtypes ofAML (Fenaux et al, 1990).
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Mouse leukaemia Mm-A cells exhibit several monocyte-associ-
ated phenotypes and induce monocytic leukaemia in syngeneic SL
mice (Kasukabe et al, 1984). The leukaemic mouse inoculated
with Mm-A cells is a good experimental model of AMMOL. AN-
9 possessed low toxicity and displayed anti-tumour activity in B16
melanoma and Lewis lung carcinoma models (Rephaeli et al,
1991; Nudelman et al, 1992), as well as the Mm-A monocytic
leukaemia model. Combination therapy with DNR and AN-9 is
definitely more effective than therapy with DNR alone in the
leukaemic mice inoculated with Mm-A cells. Human monocytoid
leukaemia cell lines had similar sensitivity to AN-9 in inhibiting
cell growth (Table 1). Since synergy requires the use ofonly mini-
mally toxic drug concentrations, the approach is preferred over
maximally tolerated dose regimens that are highly toxic to the
host. With respect to AMMOL, more effective therapy with fewer
side-effects might be achieved with a combination of DNR and
AN-9. Further experiments on the synergistic effects of AN-9 and
DNR should result in the development of new strategies of
AMMOL therapy.
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